Stephanie Hawkins
Obstetrics & Gynecology · Columbus, OHNPI 1306979661
Payments from drug & device makers
Across 62 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$533
- Exeltis, USA Inc.$162
- AstraZeneca$119
- Novo Nordisk$105
- Sumitomo Pharma America, Inc.$96
- Myovant Sciences Inc.$58
- plus $375 from 14 others
What the payments were for
- Food & beverage$1,448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $533 |
| Exeltis, USA Inc. | 10 | $162 |
| AstraZeneca | 1 | $119 |
| Novo Nordisk | 1 | $105 |
| Sumitomo Pharma America, Inc. | 5 | $96 |
| Myovant Sciences Inc. | 4 | $58 |
| Calliditas Therapeutics US Inc. | 3 | $58 |
| Mayne Pharma Commercial LLC | 3 | $51 |
| Sage Therapeutics, LLC | 2 | $37 |
| Agile Therapeutics, Inc. | 2 | $34 |
| Virtus Pharmaceuticals LLC | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Coopersurgical, Inc. | 2 | $25 |
| Bayer | 1 | $21 |
| Avion Pharmaceuticals | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Avanos Medical | 1 | $15 |
| Merck | 1 | $14 |
| Pfizer | 1 | $13 |
| Aspira Women's Health Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,448 in reported general payments places this provider in the 65th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $16,895 |
| Estradiol | 90 | $3,528 |
| Estradiol (Twice Weekly)Estradiol | 18 | $1,559 |
| DottiEstradiol | 15 | $1,538 |
| Medroxyprogesterone Acetate | 18 | $90 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $31 | $16,89516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Other obstetrics & gynecology in Columbus
- Harold GreenColumbus$2.3M
- Michelle IsleyColumbus$252K
- Katherine RivlinColumbus$217K
- Milroy SamuelColumbus$208K
- Uma AnanthColumbus$120K
- Erin OlahColumbus$97K
- David PortmanColumbus$94K
- Anita SomaniColumbus$93K
- Mervyn SamuelColumbus$92K
- Jacqueline RohlColumbus$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.